HitIQ Limited (AU:HIQ) has released an update.
HitIQ Limited, a leader in concussion management technologies, has announced the approval of a US Patent for its Nexus™ technology – a significant milestone that strengthens the company’s IP protection and commercial advantage. The newly patented technology focuses on data processing from an instrumented mouthguard, distinguishing real impacts from false positives, which is crucial for delivering accurate field data. The approval is expected to enhance HitIQ’s commercial opportunities in the US, the company’s primary market.
For further insights into AU:HIQ stock, check out TipRanks’ Stock Analysis page.
